UBS AM
KITE

UBS AM’s Kite Pharma, Inc. KITE Stock Holding History

UBS AM’s Portfolio KITE Stock Details KITE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-97,160
Closed -$17.5M – 2650
2017
Q3 		$17.5M Sell
97,160
-183,290
-65% -$25.5M 0.02% 760
2017
Q2 		$29.1M Sell
280,450
-32,118
-10% -$2.62M 0.03% 599
2017
Q1 		$24.5M Sell
312,568
-91,569
-23% -$5.66M 0.03% 648
2016
Q4 		$18.1M Buy
404,137
+11,291
+3% +$554K 0.02% 717
2016
Q3 		$21.9M Sell
392,846
-14,390
-4% -$802K 0.02% 649
2016
Q2 		$20.4M Buy
407,236
+29,658
+8% +$1.46M 0.02% 672
2016
Q1 		$17.3M Buy
377,578
+10,167
+3% +$492K 0.02% 708
2015
Q4 		$22.6M Sell
367,411
-53,206
-13% -$3.75M 0.03% 626
2015
Q3 		$23.4M Sell
420,617
-1,782
-0.4% -$112K 0.03% 633
2015
Q2 		$25.8M Buy
422,399
+93,599
+28% +$5.34M 0.02% 632
2015
Q1 		$19M Buy
328,800
+319,500
+3,435% +$21.4M 0.02% 723
2014
Q4 		$536K Sell
9,300
-66,300
-88% -$2.79M ﹤0.01% 1911
2014
Q3 		$2.15M Buy
+75,600
New +$1.87M ﹤0.01% 1279

UBS AM's KITE Position: Q4 2017 in Review

UBS AM sold out of Kite Pharma, Inc. (KITE) in Q4 2017, closing a stake of 97,160 shares — an estimated $17.5M sold.

UBS AM first reported a position in KITE in Q3 2014 and held it in 13 quarters. The position peaked at $29.1M in Q2 2017. 0 funds tracked by Wall St. Rank hold KITE as of Q4 2017.

  • UBS AM reported no remaining Kite Pharma, Inc. position as of Q4 2017 after selling out during the quarter.
  • UBS AM sold 97,160 Kite Pharma, Inc. shares in Q4 2017, an estimated $17.5M.
  • UBS AM first reported a position in Kite Pharma, Inc. in Q3 2014 and held it in 13 quarters.
  • UBS AM's Kite Pharma, Inc. position peaked at $29.1M in Q2 2017.
  • 0 funds tracked by Wall St. Rank held Kite Pharma, Inc. as of Q4 2017.

Based on UBS AM's 13F filing for Q4 2017, filed 9 Feb 2018.